Charles Schwab Investment Management Inc Genprex, Inc. Transaction History

Charles Schwab Investment Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	BUY	$1.82 - $3.5 $54,130 - $104,097	29,742 New	29,742 $68,000
Q3 2021 Nov 16, 2021	SELL	$2.59 - $3.36 $51,232 - $66,464	-19,781 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$3.11 - $4.87 $191,218 - $299,431	-61,485 Reduced 75.66%	19,781 $67,000
Q3 2020 Nov 13, 2020	BUY	$2.9 - $4.29 $57,364 - $84,860	19,781 Added 32.17%	81,266 $274,000
Q2 2020 Aug 14, 2020	BUY	$1.99 - $3.64 $122,355 - $223,805	61,485 New	61,485 $194,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $76.8M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.